Evidence map›Paper›PMID 32178357›Full record

ArticleMolecules (Basel, Switzerland)2020

Enhancing the Immune Response of a Nicotine Vaccine with Synthetic Small "Non-Natural" Peptides.

Hoang-Thanh Le, Nya L Fraleigh, Jordan D Lewicky, Justin Boudreau, Paul Dolinar, Nitin Bhardwaj, Francisco Diaz-Mitoma, Sabine Montaut, Sarah Fallahi, Alexandrine L Martel

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Hoang-Thanh LeHealth Sciences North Research Institute, 56 Walford Road, Sudbury, ON P3E 2H3, Canada.
Nya L FraleighHealth Sciences North Research Institute, 56 Walford Road, Sudbury, ON P3E 2H3, Canada.
Jordan D LewickyHealth Sciences North Research Institute, 56 Walford Road, Sudbury, ON P3E 2H3, Canada.
Justin BoudreauHealth Sciences North Research Institute, 56 Walford Road, Sudbury, ON P3E 2H3, Canada.
Paul DolinarHealth Sciences North Research Institute, 56 Walford Road, Sudbury, ON P3E 2H3, Canada.
Nitin BhardwajDivision of Comparative Medicine, University of Toronto, 1 King's College Circle, Toronto, ON M5S 1A8, Canada.
Francisco Diaz-MitomaNorthern Ontario School of Medicine, 935 Ramsey Lake Road, Sudbury, ON P3E 2C6, Canada.
Sabine MontautDepartment of Chemistry and Biochemistry, Biomolecular Sciences Programme, Laurentian University, 935 Ramsey Lake Road, Sudbury, ON P3E 2C6, Canada.ORCID 0000-0002-8223-4809
Sarah FallahiHealth Sciences North Research Institute, 56 Walford Road, Sudbury, ON P3E 2H3, Canada.
Alexandrine L MartelHealth Sciences North Research Institute, 56 Walford Road, Sudbury, ON P3E 2H3, Canada.
Health Sciences North · CALaurentian University · CAUniversity of Toronto · CAVariation Biotechnologies (Canada) · CA

Funding

Canadian Foundation for Innovation Leaders Opportunity FundCIHR PJT-148531Grand Challenges Canada S4-0212-01Natural Sciences and Engineering Research Council of Canada Research Tools and Instruments ProgramNorthern Cancer Foundation 2013-2015
6 · The paper itself

Abstract

The addictive nature of nicotine is likely the most significant reason for the continued prevalence of tobacco smoking despite the widespread reports of its negative health effects. Nicotine vaccines are an alternative to the currently available smoking cessation treatments, which have limited efficacy. However, the nicotine hapten is non-immunogenic, and successful vaccine formulations to treat nicotine addiction require both effective adjuvants and delivery systems. The immunomodulatory properties of short, non-natural peptide sequences not found in human systems and their ability to improve vaccine efficacy continue to be reported. The aim of this study was to determine if small "non-natural peptides," as part of a conjugate nicotine vaccine, could improve immune responses. Four peptides were synthesized via solid phase methodology, purified, and characterized.

Indexed as

Adjuvants, ImmunologicAnimalsChromatography, High Pressure LiquidDrug Delivery SystemsHaptensHumansImmunityInterleukin-1betaMiceNicotinePeptidesSubstance-Related DisordersTobacco Use DisorderVaccines, ConjugateVaccines, SubunitAdjuvants, ImmunologicHaptensIL1B protein, mouseInterleukin-1betaNicotinePeptidesVaccines, ConjugateVaccines, Subunitbacterial derived adjuvantdendritic cellsIL-1βimmune responsesmacrophagesnon-natural peptidespeptide solid phase synthesisphagocytic cellsvaccine delivery

Identifiers

PMID32178357
PMCPMC7143940
OpenAlexW3011011396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.